Table 5 Main characteristics and treatments of pituitary tumours in our series of MEN1 patients
From: Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients
Pituitary tumours | Patients n. (%) | Clinical presentation | Surgery | Pharmacological treatment Dopamine agonist (Cabergoline) n. (%) | |||
|---|---|---|---|---|---|---|---|
FTs n. (%) | NFAs n. (%) | Combination of FTs n. (%) | No surgery n. (%) | Transphenoidal resection n. (%) | |||
Total patients with pituitary tumours | 75 (51.72)%) | 62 (42.76%) - 59 PRLomas (40.69%) - 3 corticotropinoma (2.07%) | 12 (8.28%) | 1 (0.69%) - 1 PRLoma-1 somatotropinoma (0.69%) | 64 (85.33%) | 11 (14.67%) | 30 (40%) |
A pituitary tumour as first clinical manifestation | 25 (17.24%) | 25 (17.24%) - 24 PRLomas (16.55%) - 1 corticotropinoma (0,69%) | 0 | 0 | 18 (24%) | 7 (9.33%) | 10 (13.33%) |
Index cases (probands) | 54 (37.24%) | 44 (30.34%) - 41 PRLomas (28.28%) - 3 corticotropinoma (2.07%) | 9 (6.21%) | 1 (0.69%) - 1 PRLoma-1 somatotropinoma (0.69%) | 44 (58.67%) | 10 (13.33%) | 17 (22.67%) |
Relatives | 21 (14.48%) | 18 (12.41%) - 18 PRLomas (12.41%) | 3 (2.07% | 0 | 20 (26.67%) | 1 (1.33%) | 13 (17.33%) |